Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes
This clinical trial aimed to evaluate a combination therapy of sitagliptin, lansoprazole, and Diamyd to preserve beta cell function in newly diagnosed Type 1 Diabetes (T1D) patients. The study was terminated due to changes in study personnel before full subject accrual.
Indication: Diabetes Mellitus Type 1
Modality: small molecule
Target: Beta cell function in Type 1 Diabetes
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Source URL: ClinicalTrials.gov
Source updated: Jan 03, 2013
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Beta cell function in Type 1 Diabetes
View original source fields
Condition raw: Diabetes Mellitus Type 1
Condition normalized: Diabetes Mellitus Type 1
Modality raw: Diabetes Mellitus Type 1
Modality normalized: small molecule
Target raw: Beta cell function in Type 1 Diabetes
Target normalized: Beta cell function in Type 1 Diabetes